A detailed history of Barclays PLC transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 193,873 shares of LXRX stock, worth $137,649. This represents 0.0% of its overall portfolio holdings.

Number of Shares
193,873
Previous 193,873 -0.0%
Holding current value
$137,649
Previous $304,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$1.51 - $2.39 $233,198 - $369,102
154,436 Added 391.6%
193,873 $304,000
Q2 2024

Aug 14, 2024

SELL
$1.54 - $2.28 $38,780 - $57,414
-25,182 Reduced 38.97%
39,437 $66,000
Q1 2024

May 15, 2024

SELL
$1.3 - $3.58 $81,116 - $223,381
-62,397 Reduced 49.13%
64,619 $155,000
Q4 2023

Feb 15, 2024

BUY
$1.0 - $1.53 $87,827 - $134,375
87,827 Added 224.11%
127,016 $195,000
Q3 2023

Nov 07, 2023

BUY
$1.06 - $2.33 $1,611 - $3,541
1,520 Added 4.04%
39,189 $42,000
Q2 2023

Aug 03, 2023

SELL
$2.15 - $3.49 $9,948 - $16,148
-4,627 Reduced 10.94%
37,669 $86,000
Q1 2023

May 04, 2023

BUY
$1.99 - $2.68 $39,672 - $53,428
19,936 Added 89.16%
42,296 $103,000
Q4 2022

Feb 13, 2023

BUY
$1.8 - $2.56 $33,892 - $48,202
18,829 Added 533.25%
22,360 $42,000
Q3 2022

Nov 03, 2022

SELL
$1.94 - $3.43 $139,142 - $246,009
-71,723 Reduced 95.31%
3,531 $8,000
Q2 2022

Aug 12, 2022

SELL
$1.31 - $2.69 $10,457 - $21,474
-7,983 Reduced 9.59%
75,254 $140,000
Q1 2022

May 16, 2022

SELL
$1.95 - $3.89 $3,379 - $6,741
-1,733 Reduced 2.04%
83,237 $175,000
Q4 2021

Feb 14, 2022

BUY
$3.81 - $6.16 $218,019 - $352,493
57,223 Added 206.23%
84,970 $335,000
Q3 2021

Nov 09, 2021

BUY
$3.38 - $5.35 $48,999 - $77,558
14,497 Added 109.41%
27,747 $134,000
Q2 2021

Aug 13, 2021

SELL
$4.12 - $5.87 $116,917 - $166,578
-28,378 Reduced 68.17%
13,250 $60,000
Q1 2021

May 13, 2021

BUY
$3.45 - $9.09 $97,455 - $256,774
28,248 Added 211.12%
41,628 $244,000
Q4 2020

Feb 11, 2021

SELL
$1.05 - $3.67 $6,067 - $21,208
-5,779 Reduced 30.16%
13,380 $46,000
Q3 2020

Nov 12, 2020

SELL
$1.44 - $2.1 $178,372 - $260,127
-123,870 Reduced 86.6%
19,159 $27,000
Q2 2020

Aug 12, 2020

BUY
$1.75 - $2.3 $126,962 - $166,865
72,550 Added 102.94%
143,029 $287,000
Q1 2020

May 13, 2020

BUY
$1.8 - $4.28 $22,275 - $52,965
12,375 Added 21.3%
70,479 $138,000
Q4 2019

Feb 10, 2020

BUY
$3.16 - $5.15 $104,596 - $170,465
33,100 Added 132.38%
58,104 $241,000
Q3 2019

Nov 14, 2019

SELL
$1.2 - $6.66 $2,460 - $13,653
-2,050 Reduced 7.58%
25,004 $75,000
Q2 2019

Aug 14, 2019

BUY
$5.35 - $7.11 $58,550 - $77,811
10,944 Added 67.93%
27,054 $170,000
Q1 2019

May 15, 2019

BUY
$4.36 - $7.94 $58,873 - $107,213
13,503 Added 517.95%
16,110 $89,000
Q4 2018

Feb 14, 2019

SELL
$6.15 - $10.51 $123,258 - $210,641
-20,042 Reduced 88.49%
2,607 $18,000
Q3 2018

Nov 14, 2018

BUY
$10.32 - $13.06 $201,085 - $254,474
19,485 Added 615.83%
22,649 $241,000
Q2 2018

Aug 14, 2018

SELL
$7.8 - $13.69 $123,240 - $216,302
-15,800 Reduced 83.32%
3,164 $38,000
Q1 2018

May 15, 2018

SELL
$7.86 - $11.39 $308,748 - $447,410
-39,281 Reduced 67.44%
18,964 $163,000
Q4 2017

Feb 14, 2018

BUY
$8.77 - $12.28 $174,294 - $244,052
19,874 Added 51.79%
58,245 $575,000
Q3 2017

Nov 14, 2017

BUY
$12.17 - $16.3 $466,975 - $625,447
38,371
38,371 $471,000

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $134M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.